BioMotiv to develop BioAtla’s TH22 pathway-directed antibody for IBD, oncologic indications

In conjunction with the licensing deal, BioMotiv has established Kodosil Bio which will develop all compounds resulting from the license.

BioAtla president and CEO Jay Short said the company believes that BioMotiv will be an ideal partner to take the antibody forward into the clinic, building on its solid discovery foundation that shows the value of this antibody in the potential treatment of a variety of disease indications where there is considerable unmet need in large market opportunities.

"This partnership is an ideal demonstration of the power of our proprietary platform to generate unique, therapeutically-active monoclonal antibodies for a variety of diseases, both for our partners — in this case BioMotiv — and for our proprietary product portfolio," Short said.

BioAtla used its Comprehensive Integrated Antibody Optimization (CIAO!) platform for the identification, humanization and optimization of the monoclonal antibody.

The CIAO! technology selects antibody candidates that integrate key features of manufacturing and process development into the protein design.

The platform selects candidates with natural protein folding and glycosylation, high protein expression and faster downstream process development characteristics, providing cost and time efficiencies all through the development process.

Under the deal, BioAtla will provide its discovery and preclinical development processes for the licensed compounds, while Kodosil Bio will manage the development of the therapeutic antibody and will fund all discovery and development activities through clinical proof-of-concept.

In return, BioAtla will receive milestone payments and royalties on sales of all potential therapeutics developed through the collaboration.

If the therapeutic antibody products developed by Kodosil Bio are sublicensed or divested, BioAtla will get a substantial portion of proceeds resulting from the action.